Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
14,078
Total Claims
$1.3M
Drug Cost
258
Beneficiaries
$5,016
Cost/Patient
Risk Score Breakdown 18/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
+345%
Cost per patient vs peers
$5,016 vs $1,128 avg
+94%
Brand preference vs peers
16.3% vs 8.4% avg
Brand vs Generic
Brand: 2,189 claims · $1.1M
Generic: 11,214 claims · $115K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 441 | $283K |
| Insulin Glargine,hum.Rec.Anlog | 261 | $159K |
| Empagliflozin | 223 | $158K |
| Insulin Aspart | 148 | $116K |
| Insulin Glargine,hum.Rec.Anlog | 160 | $59K |
| Budesonide/Formoterol Fumarate | 90 | $39K |
| Linagliptin | 61 | $37K |
| Sitagliptin Phos/Metformin Hcl | 50 | $35K |
| Insulin Lispro | 37 | $34K |
| Linaclotide | 36 | $21K |
| Semaglutide | 22 | $21K |
| Insulin Aspart Prot/Insuln Asp | 21 | $19K |
| Insulin Aspart | 32 | $16K |
| Liraglutide | 14 | $15K |
| Ticagrelor | 29 | $14K |
Prescribing Profile
Patient Profile
70
Avg Age
39%
Female
1.37
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data